UPDATE 1-Moderna says US FDA refuses to review its influenza vaccine

Moderna -1.85%

Moderna

MRNA

52.40

-1.85%

Adds details in paragraph 2-3

- Moderna MRNA.O said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine.

The company said it had exercised a priority review voucher to fast track its application.

Moderna said it has requested a meeting with the regulator to understand the path forward.



Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via